Neutralization of CXCL12 attenuates established pulmonary hypertension in rats.
Fiche publication
Date publication
juin 2019
Journal
Cardiovascular research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GALZI Jean-Luc, Pr HIBERT Marcel, Dr BONNET Dominique
Tous les auteurs :
Bordenave J, Thuillet R, Tu L, Phan C, Cumont A, Marsol C, Huertas A, Savale L, Hibert M, Galzi JL, Bonnet D, Humbert M, Frossard N, Guignabert C
Lien Pubmed
Résumé
The progressive accumulation of cells in pulmonary vascular walls is a key pathological feature of pulmonary arterial hypertension (PAH) that results in narrowing of the vessel lumen, but treatments targeting this mechanism are lacking. The C-X-C motif chemokine 12 (CXCL12) appears to be crucial in these processes. We investigated the activity of two CXCL12 neutraligands on experimental PH, using two complementary animal models.
Mots clés
Pulmonary arterial hypertension, animal model, chemokine, stromal cell-derived factor 1, therapeutic target, vascular remodelling
Référence
Cardiovasc. Res.. 2019 Jun 7;: